1. Scrip
  2. >>Business
  3. >>Deals

Janssen Follows AbbVie To Exit From Morphic Deal, But Lead Asset Still Has Chance

 
• By Alaric DeArment

Morphic said that Janssen had chosen to exit the partnership formed in 2019, just a little more than half a year after AbbVie did the same.

Janssen exited its four-year-old deal with Morphic • Source: Shutterstock

In the space of just over half a year, Morphic Therapeutic, Inc. has lost two partnerships with major biopharma companies to develop its orally available integrin inhibitor drugs. However, the company still has growth prospects in the form of a Phase IIa asset in ulcerative colitis.

In a Securities and Exchange Commission filing on 20 January, Morphic said it had received notice from Johnson & Johnson’s Janssen Pharmaceuticals, Inc. subsidiary that the drug maker had elected to terminate a partnership between the two companies dating back to early 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.